LIFECORE BIOMEDICAL, INC. \DE\ 8-K

What Happened Lifecore Biomedical, Inc. (LFCR) announced consolidated financial results for the fourth quarter and transition period ended December 31, 2025 via a press release issued March 16, 2026. The company also made investor presentation materials available on its website the same day. The press release and presentation were furnished as Exhibits 99.1 and 99.2 to the Form 8-K filed March 16, 2026 (Item 2.02 and Item 7.01). The filing was signed by CFO Ryan D. Lake.

Key Details

• Press release dated March 16, 2026 reporting consolidated results for the quarter and transition period ended December 31, 2025 (Exhibit 99.1).
• Investor Presentation posted March 16, 2026 and furnished as Exhibit 99.2 (Regulation FD disclosure).
• Form 8-K filed March 16, 2026; signed by Chief Financial Officer Ryan D. Lake.
• Filing items: 2.02 (results of operations and financial condition) and 7.01 (Regulation FD disclosure).

Why It Matters This 8-K provides Lifecore’s latest official quarterly financial update and accompanying investor materials, which investors should review to see revenue, earnings, cash flow and any management commentary that could affect valuation or near-term outlook. The furnished press release and presentation are primary sources for updated results and guidance-related commentary; retail investors should read them before making investment decisions.